Thailand Insulin Drugs and Delivery Devices Market Size and Share
Market Overview
| Study Period | 2021 - 2032 |
|---|---|
| Forecast Data Period | 2027 - 2032 |
| Base Year Market Size (2026) | USD 129.52 Million |
| Market Size (2027) | USD 134 Million |
| Market Size (2032) | USD 158.85 Million |
| Growth Rate (2027 - 2032) | 3.46 % |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Thailand Insulin Drugs and Delivery Devices Market Analysis by Mordor Intelligence
The Thailand Insulin Drugs And Delivery Devices Market size is expected to grow from USD 129.52 million in 2026 to USD 134 million in 2027 and is forecast to reach USD 158.85 million by 2032 at 3.46% CAGR over 2027-2032.
Patients with diabetes infected with COVID-19 were at risk of a severe disease course and mortality. Several factors such as impaired immune response and increased inflammatory response contributed to the increased disease severity. Doctors and health workers in Thailand used new methods for consultation and dispensing medicines to serious noncommunicable disease patients with limited mobility. After reviewing their electronic health records, noncommunicable disease case managers would contact Health Promoting Hospital staff and Community Health Volunteers and arrange for check-ups for hypertension and diabetes at home before prescribing medicines.
People with type 1 diabetes cannot produce adequate insulin because their immune system attacks their insulin-producing beta cells while people with type 2 diabetes have insulin resistance and do not make enough insulin. Diabetes patients take insulin, through an injection (syringe or pen), a pump, or in inhaled form. Thailand is facing increasing numbers of patients with diabetes due to unhealthy diets, high obesity rates, and an aging society. Like other countries in the Western Pacific region, the disease detection rate in Thailand has improved in recent years, but glycemic control remains suboptimal and significant numbers of patients suffer from complications.
Diabetes is a considerable burden as it reduces the quality of life, increases mortality, and drives up healthcare costs. The Thai government is attempting to address the threat of diabetes mellitus through programs, like ‘Thailand Healthy Lifestyle Strategic Plan 2011-2020’. Such programs will help diabetic patients understand the benefits of various diabetes products available in the market.
Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.
Thailand Insulin Drugs and Delivery Devices Market Trends and Insights
Rising diabetes prevalence
In Thailand, Diabetes Population is expected to increase with a CAGR greater than 0.76% over the forecast period.
According to Mordor Intelligence, an estimated 0.44 million people are living with diabetes in Thailand in the current year. Thailand is facing an increase in the number of diabetes patients due to a sedentary lifestyle which is more common in urban areas of Thailand. Diabetes self-management education has not yet been standardized and a multidisciplinary team approach is not widely utilized. The local initiatives have targeted reductions in specific complications, including retinopathy and diabetic foot problems, which has resulted in better disease prevention and treatment.
According to the World Health Organization estimated latest estimates, around 11% of the total health expenditure in Thailand is allocated to diabetes care, which is comparable to other countries in the region. By 2030, this figure is expected to grow by 41%, effectively doubling the societal burden of diabetes. Universal healthcare coverage has increased access to care, but inequality exists between different health plans, and non-medication diabetes supplies are not yet widely covered. In Thailand, three out of five people with diabetes who receive care do not achieve the recommended treatment targets.
Therefore, owing to the increasing diabetes prevalence the studied market is anticipated to grow over the analysis period.
The Insulin Syringes Segment is Expected to Witness Highest Growth Rate Over the Forecast Period
The Insulin Syringe Segment is expected to grow with a CAGR of more than 4.9% in the market during the forecast period.
Type 1 diabetes is caused due to the inability of the pancreas to produce insulin. Hence, type 1 patients are mostly prescribed the intake of the hormone. Usually, doctors prescribe type 2 diabetes patients to take Insulin through external sources like an Insulin syringe. The Insulin syringe can be used by any diabetic patient to take Insulin as per the recommendation of a medical expert. However, depending on the type and brand, all types of Insulin cannot be used through an Insulin syringe.
Insulin syringes continue to play an important role in diabetes management in Thailand due to their affordability, widespread availability, and suitability for long-term insulin therapy. Compared with advanced insulin delivery devices, syringes offer a cost-effective option for patients requiring regular insulin administration. Their simple design, accurate dose measurement, and compatibility with various insulin formulations support their continued utilization, particularly among price-sensitive patient populations, contributing to stable demand in the Thailand insulin drugs and delivery devices market.
Thailand adopted universal health coverage, moving away from a system funded primarily by out-of-pocket payments to one funded by a mix of taxes and insurance contributions. The government is working on establishing new policy programs that can reduce the burden of healthcare costs for diabetes treatment. Along with strategic public health planning, increased collaboration between private and public sectors, enhanced professional training, increased use of technology and data management, and equitable distribution of care are all needed to improve the outcomes of patients with diabetes in Thailand.
The aforementioned factors are likely to drive segment growth during the forecast period.
Competitive Landscape
The Thailand Insulin Drugs and Delivery Devices Market is consolidated, with few significant and generic players. Mergers and acquisitions that happened between the players in the recent past have helped the companies strengthen their market presence.
Thailand Insulin Drugs and Delivery Devices Industry Leaders
-
Novo Nordisk
-
Medtronic
-
Sanofi
-
Eli Lilly
-
Becton Dickinson
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- July 2023: The World Health Organization (WHO) published the Executive Summary of the 2023 update of the Model List of Essential Medicines (EML) consisting of the inclusion of human insulin cartridges and pre-filled human insulin pens in this list and the benefits this could yield for people living with diabetes.
- May 2023: Medtronic plc announced it has entered into a set of definitive agreements to acquire EOFlow Co. Ltd., manufacturer of the EOPatch device - a tubeless, wearable, and fully disposable insulin delivery device. The addition of EOFlow, together with Medtronic's Meal Detection Technology algorithm and next-generation continuous glucose monitor (CGM), is expected to expand the company's ability to address the needs of more individuals with diabetes.
Thailand Insulin Drugs and Delivery Devices Market Report Scope
Insulin drugs are prescription drugs that contain insulin and are used to treat diabetes mellitus using an insulin pump, smart pen, syringe, or other devices. The Thailand Insulin Drugs and Delivery Devices Market is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD) and volume for insulin drugs and the devices (in units) for the above segments.
| Basal or Long-acting Insulins | Lantus (Insulin Glargine) |
| Levemir (Insulin Detemir) | |
| Toujeo (Insulin Glargine) | |
| Tresiba (Insulin Degludec) | |
| Basaglar (Insulin Glargine) | |
| Bolus or Fast-acting Insulins | NovoRapid/Novolog (Insulin aspart) |
| Humalog (Insulin lispro) | |
| Apidra (Insulin glulisine) | |
| FIASP (Insulin aspart) | |
| Admelog (Insulin lispro Sanofi) | |
| Traditional Human Insulins | Novolin/Mixtard/Actrapid/Insulatard |
| Humulin | |
| Insuman | |
| Combination Insulins | NovoMix (Biphasic Insulin aspart) |
| Ryzodeg (Insulin degludec and Insulin aspart) | |
| Xultophy (Insulin degludec and Liraglutide) | |
| Soliqua/Suliqua (Insulin glargine and Lixisenatide) | |
| Biosimilar Insulins | Insulin Glargine Biosimilars |
| Human Insulin Biosimilars |
| Insulin Pumps | Insulin Pump Devices |
| Insulin Pump Reservoirs | |
| Insulin Infusion sets | |
| Insulin Pens | Cartridges in reusable pens |
| Disposable insulin pens | |
| Insulin Syringes | |
| Insulin Jet Injectors |
| Drug | Basal or Long-acting Insulins | Lantus (Insulin Glargine) |
| Levemir (Insulin Detemir) | ||
| Toujeo (Insulin Glargine) | ||
| Tresiba (Insulin Degludec) | ||
| Basaglar (Insulin Glargine) | ||
| Bolus or Fast-acting Insulins | NovoRapid/Novolog (Insulin aspart) | |
| Humalog (Insulin lispro) | ||
| Apidra (Insulin glulisine) | ||
| FIASP (Insulin aspart) | ||
| Admelog (Insulin lispro Sanofi) | ||
| Traditional Human Insulins | Novolin/Mixtard/Actrapid/Insulatard | |
| Humulin | ||
| Insuman | ||
| Combination Insulins | NovoMix (Biphasic Insulin aspart) | |
| Ryzodeg (Insulin degludec and Insulin aspart) | ||
| Xultophy (Insulin degludec and Liraglutide) | ||
| Soliqua/Suliqua (Insulin glargine and Lixisenatide) | ||
| Biosimilar Insulins | Insulin Glargine Biosimilars | |
| Human Insulin Biosimilars | ||
| Device | Insulin Pumps | Insulin Pump Devices |
| Insulin Pump Reservoirs | ||
| Insulin Infusion sets | ||
| Insulin Pens | Cartridges in reusable pens | |
| Disposable insulin pens | ||
| Insulin Syringes | ||
| Insulin Jet Injectors | ||
Key Questions Answered in the Report
How big is the Thailand Insulin Drugs And Delivery Devices Market?
The Thailand Insulin Drugs And Delivery Devices Market size is expected to reach USD 129.52 million in 2026 and grow at a CAGR of 3.46% to reach USD 158.85 million by 2032.
What is the Thailand Insulin Drugs And Delivery Devices Market size in 2027?
In 2027, the Thailand Insulin Drugs And Delivery Devices Market size is expected to reach USD 134.00 million.
Who are the key players in Thailand Insulin Drugs And Delivery Devices Market?
Novo Nordisk, Medtronic, Sanofi, Eli Lilly and Becton Dickinson are the major companies operating in the Thailand Insulin Drugs And Delivery Devices Market.
What years does this Thailand Insulin Drugs And Delivery Devices Market cover, and what was the market size in 2025?
In 2025, the Thailand Insulin Drugs And Delivery Devices Market size was estimated at USD 125.19 million. The report covers the Thailand Insulin Drugs And Delivery Devices Market historical market size for years: 2021, 2022, 2023, 2024, 2025, and 2026. The report also forecasts the Thailand Insulin Drugs And Delivery Devices Market size for years: 2027, 2028, 2029, 2030, 2031, and 2032.